HER2-low breast cancer: the ESMO Expert Consensus Statements

How to navigate into the emerging landscape of HER2-low breast cancer? The ESMO Expert Consensus statements on the definition, diagnosis, and management of HER2-low breast cancer aim to address major controversies stemming from recent research in the field.

Fine-tuning of the HER2-low pathologic diagnosis, along with accumulation of more clinical data in the field, will help to fully unlock the benefit of novel anti-HER2 antibody-drug conjugates in the coming years and possibly inform the targeting of HER2-low expression in tumour types beyond breast cancer.

Full publication: https://www.annalsofoncology.org/article/S0923-7534(23)00693-2/fulltext

The ESMO Expert Consensus Statement series of publications contain recommendations on well-defined, controversial or clinically-relevant topics and are produced by 20-40 key experts in the field. You can find the full list of publications here: https://www.esmo.org/guidelines/esmo-expert-consensus-statements

Produced by the European Society for Medical Oncology

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.